UNLABELLED: Congenital erythropoietic porphyria (CEP; Gunther disease; OMIM 263700) is a rare autosomal recessive disorder caused by a deficiency of uroporphyrinogen III synthase (UROS). The deficiency of this enzyme is associated with lifelong overproduction of series I porphyrins which circulate and are deposited in many tissues, causing light-sensitisation and severe damage to skin beginning in childhood. Blistering and scarring of exposed areas may lead to mutilating deformities. We describe two cases: a 4-year-old boy and his first cousin who were cured of CEP by matched unrelated donor bone marrow transplants. Both are alive and disease-free 3 and 2 years post-transplant, respectively. Cutaneous lesions improved dramatically. The correction of the enzyme deficiency was confirmed by measuring erythrocyte UROS activity and urinary porphyrin excretion. Chimerism was complete for both children. Both patients were homoallelic for a novel mutation of the UROS gene, the missense mutation A69T. CONCLUSION: Considering the severity of the disease, if HLA-matched sibling donor is not available, haematopoietic stem cell transplantation using a matched unrelated donor should be strongly considered for treating congenital erythropoietic porphyria since this is currently the only known curative therapy.
UNLABELLED: Congenital erythropoietic porphyria (CEP; Gunther disease; OMIM 263700) is a rare autosomal recessive disorder caused by a deficiency of uroporphyrinogen III synthase (UROS). The deficiency of this enzyme is associated with lifelong overproduction of series I porphyrins which circulate and are deposited in many tissues, causing light-sensitisation and severe damage to skin beginning in childhood. Blistering and scarring of exposed areas may lead to mutilating deformities. We describe two cases: a 4-year-old boy and his first cousin who were cured of CEP by matched unrelated donor bone marrow transplants. Both are alive and disease-free 3 and 2 years post-transplant, respectively. Cutaneous lesions improved dramatically. The correction of the enzyme deficiency was confirmed by measuring erythrocyte UROS activity and urinary porphyrin excretion. Chimerism was complete for both children. Both patients were homoallelic for a novel mutation of the UROS gene, the missense mutation A69T. CONCLUSION: Considering the severity of the disease, if HLA-matched sibling donor is not available, haematopoietic stem cell transplantation using a matched unrelated donor should be strongly considered for treating congenital erythropoietic porphyria since this is currently the only known curative therapy.
Authors: Amr A Shady; Brandon R Colby; Luis F Cunha; Kenneth H Astrin; David F Bishop; Robert J Desnick Journal: Br J Haematol Date: 2002-06 Impact factor: 6.998
Authors: A Fontanellas; M Mendez; F Mazurier; M Cario-André; S Navarro; C Ged; L Taine; F Géronimi; E Richard; F Moreau-Gaudry; R Enriquez De Salamanca; H de Verneuil Journal: Gene Ther Date: 2001-04 Impact factor: 5.250
Authors: E Richard; M Mendez; F Mazurier; C Morel; P Costet; P Xia; A Fontanellas; F Geronimi; M Cario-André; L Taine; C Ged; P Malik; H de Verneuil; F Moreau-Gaudry Journal: Mol Ther Date: 2001-10 Impact factor: 11.454
Authors: A Fontanellas; M Bensidhoum; R Enriquez de Salamanca; A Moruno Tirado; H de Verneuil; C Ged Journal: Eur J Hum Genet Date: 1996 Impact factor: 4.246
Authors: J Frank; X Wang; H M Lam; V M Aita; F K Jugert; G Goerz; H F Merk; M B Poh-Fitzpatrick; A M Christiano Journal: Ann Hum Genet Date: 1998-05 Impact factor: 1.670
Authors: C Lagarde; D Hamel-Teillac; Y De Prost; S Blanche; C Thomas; A Fischer; Y Nordmann; C Ged; H De Verneuil Journal: Ann Dermatol Venereol Date: 1998-02 Impact factor: 0.777
Authors: David F Bishop; Annika Johansson; Robert Phelps; Amr A Shady; Maria C M Ramirez; Makiko Yasuda; Andres Caro; Robert J Desnick Journal: Am J Hum Genet Date: 2006-02-09 Impact factor: 11.025